Skip to NavigationSkip to content

HPV

Top Ten most popular articles on Pharmafile.com this week!

This week’s most popular story covered news of Trump’s claims that he will introduce an executive order to ensure the United States pays the lowest drug prices in the world. The claim comes amid lively debate around drug pricing in the United States.

Across the pond, the UK Government said it would give boys the HPV vaccine in an effort to tackle cancers. The NHS also said it would try out a subscription style payment model for antibiotics in seeking to tackle the global crisis of antimicrobial resistance (AMR).

Boys in UK to be given HPV vaccine

Image Credit: https://commons.wikimedia.org/wiki/File:Consistent_with_HPV-associated_SCC_in_muscle_--_high_mag.jpg

Boys in the United Kingdom will from September be given the human papilloma virus (HPV) vaccine, the government has said.  

Twelve and 13 year old boys will be given the HPV vaccine in an effort to prevent various forms of cancer including cervical, penile, anal and genital cancers as well as some cancers of the head and neck.

Major review points to success of HPV vaccine, cervical cancer could be eradicated in developed nations

Image Credit: http://www.scientificanimations.com/wiki-images/

A major new review published in The Lancet has supported the effectiveness of the human papilloma virus (HPV) vaccine in developed nations in reducing rates of cervical cancer, indicating that further use of the therapy could provide the chance to eliminate the disease from these countries in the coming decades.

The review examined 65 studies covering 60 million people across 14 high-income countries, including the UK, analysing HPV rates, rates of anogenital warts – which the virus can also cause – as well as pre-cancerous cells in the cervix called CIN.

HPV vaccine prevents 90% of cervical pre-cancer cases in Scotland, research shows

Routine vaccination of girls in Scotland against HPV has led to a dramatic drop in cases of cervical cancer, according to a paper published in the BMJ.

The vaccine has almost eliminated cases of cervical pre-cancer in young women since the immunisation programme was introduced ten years ago, as the number of cases fell by as much as 90%, the research says.

MSD announced collaboration with Brazilian non-profit over development of dengue vaccine

US firm Merck & Co have announced a collaboration with the Brazilian non-profit Instituto Butantan, with the intention of developing vaccines for mosquito-borne virus dengue fever.

The pair have licensed rights from the NIH’s National Institute of Allergy and Infectious Diseases for the development of live, attenuated tetravalent vaccines.

Insituto Butantan’s dengue fever vaccine candidate TV003, is currently being evaluated in a large Phase 3 study in Brazil.

US FDA approves HPV vaccine for men and women aged 27-45

The US Food and Drug Administration have approved the use of HPV vaccine Gardasil 9 for both men and woman between the ages of 27 and 45. Previously the vaccine had only been approved for those between the ages of 9 and 26.

HPV vaccine to be given to boys in England

The government has announced that boys in England aged 12 and 13 will be vaccinated against Human Papilloma Virus (HPV) a sexually transmitted virus which has been linked to various forms of cancer.

HPV vaccine slashes rate of infection by 86% in UK

Since the introduction of the vaccination against the Human Papilloma Virus in 2008, there has been an 86% drop in the incidence of infection in women aged 16 to 21.

Recurrent HPV infections are the main cause of the majority of cases of cervical cancer and the introduction of vaccination for girls aged between 12 and 13 was brought in to protect women from facing the prospect of developing the cancer.

UK Government to offer HPV vaccine to men who have sex with men

Image credit: National Cancer Institute

The UK Government has confirmed a national vaccination programme that will provide access for men who have sex with men(MSM) to protection against the human papillomavirus (HPV) in England, a disease which carries increased risk of oral, anal and penile cancers, as well as genital warts.

Calls strengthen for HPV vaccine for boys

The human papillomavirus (HPV) vaccine began to be implemented in the UK in 2008. It started by immunising girls between 12 and 13 years old, and was also offered to girls up to the age of 18 the following year, for a two year period. The aim was to immunise society through “herd protection”, not necessitating the wider immunisation of older women or of boys.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches